
ASCO25: Johnson & Johnson reports data from Phase I trial of prostate cancer drug
US-based pharmaceutical company Johnson & Johnson has reported data from a Phase I trial of its bispecific antibody, pasritamig, for metastatic castration-resistant prostate cancer (mCRPC). The first-in-human trial enrolled 174 subjects aged 36–89 …